# EDGAR Filing Document

**Accession Number:** 0001327273
**File Stem:** 0001193125-26-124494
**Filing Date:** 2026-3
**Character Count:** 6898
**Document Hash:** 42aff9ab7c78904df87367532845ccfd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-124494.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001193125-26-124494

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260325

**EFFECTIVENESS DATE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lyra Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001327273
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-237973
- **FILM NUMBER:** 26793821

**BUSINESS ADDRESS:**
- **STREET 1:** 480 ARSENAL WAY
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-373-4600

**MAIL ADDRESS:**
- **STREET 1:** 480 ARSENAL WAY
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 480 Biomedical, Inc.
- **DATE OF NAME CHANGE:** 20120927

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arsenal Vascular, Inc.
- **DATE OF NAME CHANGE:** 20110826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arsenal Medical, Inc.
- **DATE OF NAME CHANGE:** 20090414

**As filed with the Securities and Exchange Commission on March 25, 2026** 

**Registration No. 333-237973**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO** 

**FORM S-8**

**REGISTRATION STATEMENT NO. 333-237973** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Lyra Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-1700838** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**480 Arsenal Way** 

**Watertown, Massachusetts 02472** 

**(Address of principal executive offices) (Zip code)** 

**Lyra Therapeutics, Inc. 2005 Equity Incentive Plan, as amended** 

**Lyra Therapeutics, Inc. 2016 Equity Incentive Plan, as amended** 

**Lyra Therapeutics, Inc. 2020 Incentive Award Plan** 

**Lyra Therapeutics, Inc. 2020 Employee Stock Purchase Plan** 

**(Full title of the plans)** 

**Maria Palasis, Ph.D.** 

**480 Arsenal Way** 

**Watertown, Massachusetts 02472** 

**(Name and address of agent for service)** 

**(617) 393-4600** 

**(Telephone number, including area code, of agent for service)** 

***Copy to:***

**Peter N. Handrinos, Esq.** 

**Wesley C. Holmes, Esq.** 

**Latham & Watkins LLP** 

**200 Clarendon Street, 27th Floor** 

**Boston, MA 02116** 

**(617) 948-6000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

**DEREGISTRATION OF SECURITIES** 

This Post-Effective Amendment relates to the Registration Statement on Form S-8 (File No. 333-237973) (as amended, the "Registration Statement"), filed by Lyra Therapeutics, Inc., a Delaware corporation (the "Registrant"), with the Securities and Exchange Commission (the "SEC") on May 1, 2020, registering a total of 219,460 shares of the Registrant's common stock, par value $0.001 per share (the "Common Stock"), under the Registrant's 2005 Equity Incentive Plan, as amended, 682,218 shares of Common Stock under the Registrant's 2016 Equity Incentive Plan, as amended, 622,530 shares of Common Stock under the Registrant's 2020 Employee Stock Purchase Plan, and 5,880,275 shares of Common Stock under the Registrant's 2020 Incentive Award Plan. This Post-Effective Amendment is being filed to deregister any and all shares of Common Stock, registered but unsold or otherwise unissued under the Registration Statement as of the date hereof.

On February 2, 2026, the Registrant received a letter (the "Staff Determination Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Registrant that Nasdaq had determined to delist the Registrant's common stock from The Nasdaq Stock Market. In the Staff Determination Letter, Nasdaq stated that, pursuant to Listing Rule 5101, it believes the Registrant is a "public shell" and that the continued listing of its securities is no longer warranted. Trading of the Registrant's common stock was suspended at the open of trading on March 17, 2026.

As a result of the foregoing, and Nasdaq's determination that the Registrant's Common Stock is no longer suitable for listing pursuant to certain Nasdaq rules, Nasdaq plans to file a Form 25 with the SEC to remove the Registrant's common stock from listing and registration on the Nasdaq. The Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. Accordingly, the Registrant hereby terminates the effectiveness of the Registration Statement and, in accordance with an undertaking made by the Registrant in Part II of the Registration Statement to remove from registration, by means of post-effective amendment, any securities that had been registered for issuance but remain unsold at the termination of the offering, removes from registration any and all securities of the Registrant registered but unsold under the Registration Statement as of the date hereof.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on this 25 day of March, 2026.

---

| | |
|:---|:---|
| **Lyra Therapeutics, Inc.** | **Lyra Therapeutics, Inc.** |
| By: | /s/ Jason Cavalier |
| Name: | Jason Cavalier |
| Title: | Authorized Signatory |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.